This HTML5 document contains 50 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
dctermshttp://purl.org/dc/terms/
n5http://linked.opendata.cz/resource/domain/vavai/riv/tvurce/
n13http://linked.opendata.cz/ontology/domain/vavai/
shttp://schema.org/
n4http://linked.opendata.cz/ontology/domain/vavai/riv/
skoshttp://www.w3.org/2004/02/skos/core#
n9http://linked.opendata.cz/resource/domain/vavai/vysledek/RIV%2F00064165%3A_____%2F09%3A4230%21RIV10-MZ0-00064165/
n2http://linked.opendata.cz/resource/domain/vavai/vysledek/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n7http://linked.opendata.cz/ontology/domain/vavai/riv/klicoveSlovo/
n11http://linked.opendata.cz/ontology/domain/vavai/riv/duvernostUdaju/
xsdhhttp://www.w3.org/2001/XMLSchema#
n15http://linked.opendata.cz/ontology/domain/vavai/riv/jazykVysledku/
n12http://linked.opendata.cz/ontology/domain/vavai/riv/aktivita/
n16http://linked.opendata.cz/ontology/domain/vavai/riv/obor/
n14http://linked.opendata.cz/ontology/domain/vavai/riv/druhVysledku/
n8http://reference.data.gov.uk/id/gregorian-year/

Statements

Subject Item
n2:RIV%2F00064165%3A_____%2F09%3A4230%21RIV10-MZ0-00064165
rdf:type
n13:Vysledek skos:Concept
dcterms:description
The study summarizes blinded echocardiuographic analysis of long-term follow-up in patients with Fabry disease treated with alalsidase alfa. In a subset of patients, the study confirmed beneficial results on left ventricular hypertrophy. The study summarizes blinded echocardiuographic analysis of long-term follow-up in patients with Fabry disease treated with alalsidase alfa. In a subset of patients, the study confirmed beneficial results on left ventricular hypertrophy.
dcterms:title
Effect of Agalsidase Alfa Replacement Therapy on Fabry Disease-Related Hypertrophic Cardiomyopathy: A 12-to 36-Month, Retrospective, Blinded Echocardiographic Pooled Analysis Effect of Agalsidase Alfa Replacement Therapy on Fabry Disease-Related Hypertrophic Cardiomyopathy: A 12-to 36-Month, Retrospective, Blinded Echocardiographic Pooled Analysis
skos:prefLabel
Effect of Agalsidase Alfa Replacement Therapy on Fabry Disease-Related Hypertrophic Cardiomyopathy: A 12-to 36-Month, Retrospective, Blinded Echocardiographic Pooled Analysis Effect of Agalsidase Alfa Replacement Therapy on Fabry Disease-Related Hypertrophic Cardiomyopathy: A 12-to 36-Month, Retrospective, Blinded Echocardiographic Pooled Analysis
skos:notation
RIV/00064165:_____/09:4230!RIV10-MZ0-00064165
n4:aktivita
n12:V
n4:aktivity
V
n4:cisloPeriodika
9
n4:dodaniDat
n8:2010
n4:domaciTvurceVysledku
n5:5023831
n4:druhVysledku
n14:J
n4:duvernostUdaju
n11:S
n4:entitaPredkladatele
n9:predkladatel
n4:idSjednocenehoVysledku
311987
n4:idVysledku
RIV/00064165:_____/09:4230
n4:jazykVysledku
n15:eng
n4:klicovaSlova
Fabry disease; agalsidase alfa; cardiomyopathy; heart disease; left-ventricular hypertrophy; m-mode echocardiography; clinical-manifestations; cardiac manifestations; natural-history; outcome survey; beta therapy; impact; trial; galactosidase
n4:klicoveSlovo
n7:beta%20therapy n7:outcome%20survey n7:Fabry%20disease n7:cardiac%20manifestations n7:clinical-manifestations n7:heart%20disease n7:natural-history n7:m-mode%20echocardiography n7:left-ventricular%20hypertrophy n7:trial n7:agalsidase%20alfa n7:galactosidase n7:cardiomyopathy n7:impact
n4:kodStatuVydavatele
US - Spojené státy americké
n4:kontrolniKodProRIV
[0F323FA9EFB4]
n4:nazevZdroje
Clinical Therapeutics
n4:obor
n16:FA
n4:pocetDomacichTvurcuVysledku
1
n4:pocetTvurcuVysledku
4
n4:rokUplatneniVysledku
n8:2009
n4:svazekPeriodika
31
n4:tvurceVysledku
Schiffmann, R. Kampmann, C. Linhart, Aleš Devereux, RB
n4:wos
000271043100007
s:issn
0149-2918
s:numberOfPages
11